Explore more publications!
Alabama STEM News
Submit Press Release

Alabama STEM News: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Alabama STEM News.

September 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

Press releases published on November 7, 2025

Dr. Adrian Bot joins Immuthera to support the company with his unique experience in commercialization of groundbreaking cell therapies
November 7, 2025

Dr. Adrian Bot joins Immuthera to support the company with his unique experience in commercialization of groundbreaking cell therapies

Indeterminate GlobeNewswire
ESET to aid MSPs by integrating with ConnectWise Asio
November 7, 2025

ESET to aid MSPs by integrating with ConnectWise Asio

Indeterminate GlobeNewswire
Vor Bio to Participate in Upcoming Investor Conferences
November 7, 2025

Vor Bio to Participate in Upcoming Investor Conferences

Indeterminate GlobeNewswire
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
November 7, 2025

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

Indeterminate GlobeNewswire
Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting®
November 7, 2025

Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting®

Indeterminate GlobeNewswire
Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025
November 7, 2025

Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025

Indeterminate GlobeNewswire
Rivus Pharmaceuticals Announces New Data from Phase 2 M-ACCEL Trial of HU6 in MASH in Late-Breaker Oral Presentation at AASLD The Liver Meeting® 2025
November 7, 2025

Rivus Pharmaceuticals Announces New Data from Phase 2 M-ACCEL Trial of HU6 in MASH in Late-Breaker Oral Presentation at AASLD The Liver Meeting® 2025

Indeterminate GlobeNewswire
AirJoule Technologies Schedules Release of Third Quarter 2025 Results and Conference Call
November 7, 2025

AirJoule Technologies Schedules Release of Third Quarter 2025 Results and Conference Call

Indeterminate GlobeNewswire
Karbon-X Expands Blue Carbon Leadership with New Restoration Project in Guinea
November 7, 2025

Karbon-X Expands Blue Carbon Leadership with New Restoration Project in Guinea

Indeterminate GlobeNewswire
Pelthos Therapeutics Acquires Xepi® (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing
November 7, 2025

Pelthos Therapeutics Acquires Xepi® (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing

Indeterminate GlobeNewswire
Vaxart to Host Upcoming Conference Calls
November 7, 2025

Vaxart to Host Upcoming Conference Calls

Indeterminate GlobeNewswire
Biofrontera Inc. announces sale of license to Xepi® Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M
November 7, 2025

Biofrontera Inc. announces sale of license to Xepi® Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M

Indeterminate GlobeNewswire
ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2025
November 7, 2025

ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2025

Indeterminate GlobeNewswire
Dupixent® (dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (AFRS); sBLA Accepted for FDA Priority Review
November 7, 2025

Dupixent® (dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (AFRS); sBLA Accepted for FDA Priority Review

Indeterminate GlobeNewswire
illumin Reports Third Quarter 2025 Financial Results
November 7, 2025

illumin Reports Third Quarter 2025 Financial Results

Indeterminate GlobeNewswire
Copyseeker Pioneers Visual Search Integration in AI with Model Context Protocol Launch
November 7, 2025

Copyseeker Pioneers Visual Search Integration in AI with Model Context Protocol Launch

Indeterminate GlobeNewswire
Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025
November 7, 2025

Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025

Indeterminate GlobeNewswire
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 7, 2025

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting
November 7, 2025

Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting

Indeterminate GlobeNewswire
Abeona Therapeutics® Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation
November 7, 2025

Abeona Therapeutics® Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions